Apollo Hospitals will acquire a 31% stake in its wholly-owned subsidiary Apollo Health and Lifestyle (AHLL) from International Finance Corporation (IFC) for ₹1,254 crore, consolidating full ownership and control.
Upon completion, AHLL will become a 99.42% subsidiary of Apollo, with the remaining 0.58% held under the employee stock option plan (ESOP). The transaction, expected to close by November 2025, is subject to approval from the Competition Commission (CCI).
Strategic rationale for full ownership
The stake will enable Apollo Hospitals to take full control over AHLL’s operations, enabling better integration with the company’s diagnostic services and improving operational efficiencies, Apollo Hospitals said in a regulatory filing. “This acquisition is a decisive step that will allow for sharper capital allocation and a greater focus on select high-potential segments,” Suneeta Reddy, MD, Apollo Hospitals Enterprise, said.
Major push into advanced oncology
In addition, Apollo Hospitals’ board also approved an investment of ₹573 crore to set up a comprehensive oncology centre in Gurugram. The facility will include the next-generation single gantry Proteus One Proton Beam Therapy system and aims to add capacity for an additional 350 patients annually.
The centre is part of Apollo’s phase 2 expansion at Gurugram, following the first phase, with the oncology centre expected to be operational within four years. The Phase 1 development at Gurugram is on track to be commissioned by end Q4FY25 or Q1FY26, while the Proton & Integrated Cancer Centre will follow, with completion targeted over the next four years.
Apollo aims to double the scale of its oncology business to over ₹5,000 crore in 3-4 years, driven by high-end personalised care, precision medicine, and deeper penetration into India’s largest metros, along with expansion of footprint in other cities.
Shares of Apollo Hospitals closed flat at ₹7,864.50 on Friday.